BNGO Bionano Genomics, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1411690 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.2%
TTM net income YoY22.0%
TTM EPS YoY84.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin48.0%
Operating margin-97.1%
Net margin-96.9%
FCF margin—
EBITDA margin-76.0%
Returns
ROE-77.2%
ROA-48.0%
ROIC (approx.)-67.6%
Asset turnover0.50x
Leverage & solvency
Liabilities / assets39.1%
Debt / equity0.00x
Current ratio2.07x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-17.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $28.51M | $30.78M | $36.12M | $27.80M | $17.98M |
| Cost of revenue | $15.32M | $30.40M | $26.55M | $21.86M | $14.11M |
| Gross profit | $13.19M | $380,000 | $9.57M | $5.95M | $3.87M |
| R&D expense | $11.37M | $24.80M | $54.03M | $49.05M | $22.48M |
| SG&A expense | $35.15M | $51.85M | $92.76M | $88.60M | $58.49M |
| Operating income | -$33.34M | -$103.98M | -$215.25M | -$131.70M | -$77.10M |
| Interest expense | — | — | $5.12M | $298,000 | $927,000 |
| Pretax income | -$26.33M | -$111.98M | -$232.43M | -$130.71M | -$78.15M |
| Income tax | $67,000 | $33,000 | $62,000 | $1.88M | -$5.72M |
| Net income | -$26.39M | -$112.02M | -$232.49M | -$132.60M | -$72.44M |
| EBITDA | -$23.81M | -$89.96M | -$201.54M | -$122.08M | -$73.75M |
| EPS (basic) | -4.85 | -88.13 | -408.60 | -4.58 | -0.26 |
| EPS (diluted) | -4.85 | -88.13 | -408.60 | -4.58 | -0.26 |
| Weighted avg. shares (diluted) | 5.45M | 1.27M | 569,000 | 28.92M | 276.78M |
| Balance sheet | |||||
| Cash & equivalents | $2.99M | $9.17M | $17.95M | $5.09M | $24.57M |
| Short-term investments | $16.28M | $302,000 | $48.82M | $108.09M | $226.04M |
| Receivables | $5.20M | $4.75M | $9.32M | $7.02M | $4.93M |
| Inventory | $7.83M | $13.28M | $27.60M | $29.76M | $12.39M |
| Current assets | $45.39M | $39.49M | $140.12M | $157.30M | $272.41M |
| PP&E, net | $14.85M | $19.22M | $23.34M | $18.03M | $10.32M |
| Goodwill | — | — | $0 | $77.29M | $56.16M |
| Intangibles | $4.34M | $9.71M | $33.97M | $41.14M | $26.84M |
| Total assets | $73.58M | $76.67M | $214.40M | $307.50M | $377.10M |
| Current liabilities | $22.94M | $37.34M | $100.03M | $35.88M | $21.84M |
| Long-term debt | — | — | — | — | $0 |
| Total debt | — | — | — | — | $0 |
| Total liabilities | $29.16M | $41.30M | $118.25M | $58.10M | $39.98M |
| Shareholders' equity | $44.42M | $35.38M | $96.16M | $249.40M | $337.12M |
| Net debt | — | — | — | — | -$24.57M |
| Shares outstanding | 10.74M | 1.87M | 762,533 | 29.72M | 289.60M |
| Cash flow statement | |||||
| Operating cash flow | -$16.34M | -$68.92M | -$125.18M | -$124.82M | -$71.93M |
| Investing cash flow | -$12.75M | $73.84M | $24.16M | $82.77M | -$278.06M |
| Financing cash flow | $24.04M | -$13.69M | $113.81M | $23.01M | $336.11M |
| Depreciation & amortization | $9.53M | $14.02M | $13.71M | $9.62M | $3.35M |
| Stock-based compensation | $4.53M | $9.74M | $15.18M | $22.42M | $9.72M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.